RecruitingPhase 4NCT07502378

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

Studying Neurotrophic keratopathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of South Florida
Principal Investigator
Pedram Hamrah, MD
University of South Florida
Intervention
Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period.(drug)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
2026 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07502378 on ClinicalTrials.gov

Other trials for Neurotrophic keratopathy

Additional recruiting or active studies for the same condition.

See all trials for Neurotrophic keratopathy →

← Back to all trials